PRLeap - Medical & Pharmaceuticals News Releases

The Virchow Prize 2026 Awarded for Pioneering Work on Ebola, Advancing Global Epidemic Preparedness and Fostering Global Solidarity

Tue, 02 Jun 2026 07:20:00 PDT

Jean-Jacques Muyembe and Peter Piot are being honored with the international award of 500,000 for exceptional life-long leadership spanning five decades since the first outbreak of Ebola

FUTRUE Neurosciences Reaches Major Milestone

Tue, 31 Mar 2026 02:30:00 PDT

FUTRUE Neurosciences has achieved its first milestone on its mission to become the global leader in modern brain-computer interfaces (BCIs) by 2030. BCIs establish a direct interface between the human brain and digital systems.

Grünenthal licenses exclusive South Korean rights to Qutenza® to BCWorld Pharm

Thu, 05 Mar 2026 00:30:00 PST

Grünenthal, a global leader in pain management and related diseases, and BCWorld Pharm Co., Ltd. ("BCWP"), a specialty company actively expanding and diversifying its pain management portfolio through global open innovation partnerships, announced today that they have entered into a definitive agreement whereby BCWP will have the exclusive South Korean rights to Qutenza®, a topical, non-systemic, non-opioid patch treatment.

Grünenthal takes full ownership of Grünenthal Meds, the joint venture established with Kyowa Kirin for its established medicines brands

Mon, 02 Mar 2026 01:10:00 PST

Grünenthal today announced that it has acquired Kyowa Kirin International's 49% stake in 'Grünenthal Meds', taking full ownership of the company formed through a joint venture and its portfolio of established medicines.

Grünenthal's proprietary NaV 1.8 inhibitor enters clinical development

Wed, 18 Feb 2026 01:30:00 PST

Aachen, Germany, 18 February 2026 Grünenthal announced today that the first healthy volunteers have been enrolled in a Phase I trial of its voltage-gated sodium channel (NaV) 1.8 inhibitor. The orally administered investigational medicine aims to provide a non-opioid therapy option across a range of acute and chronic pain conditions. Full results of the trial are expected in the second half of 2026.

Grünenthal licenses exclusive Canadian rights to testosterone replacement therapy Nebido® to Apotex

Thu, 05 Feb 2026 07:10:00 PST

Grünenthal, a global leader in pain management and related diseases, and Apotex Inc. ("Apotex"), the largest Canadian-based pharmaceutical company, today announced they have entered into a licensing agreement whereby Apotex will have the exclusive Canadian rights to Nebido® (testosterone undecanoate), a long-acting injectable therapy indicated for the treatment of male hypogonadism (testosterone deficiency)

Internationally honored: Prof. Dietmar Jürgen Daichendt receives honorary doctorate for pioneering achievements in osteopathy and manual medicine

Fri, 28 Nov 2025 04:00:00 PST

With this award, the conferring institution recognizes not only an outstanding scientific and clinical career, but in particular the unique academic milestones that Prof. Dr. Daichendt has set in Germany.

Hessian Minister President Boris Rhein presents the Broermann Medical Innovation Award

Tue, 18 Nov 2025 07:00:00 PST

Wiesbaden, November 18, 2025 At a festive ceremony in the Hessian State Chancellery, Dr. Carl June (University of Pennsylvania) and Dr. Michel Sadelain (Columbia University) were presented with the inaugural Broermann Medical Innovation Award by Minister President Boris Rhein.

Dr. Carl June and Dr. Michel Sadelain are being awarded the Broermann Medical Innovation Award 2025

Thu, 18 Sep 2025 03:50:00 PDT

With prize money of one million euros, it is one of the most highly endowed medical awards in the world Awarded for groundbreaking pioneering work in cancer therapy using CAR-T cells Award Ceremony with Hessian Prime Minister Boris Rhein

Nominations for the Broermann Medical Innovation Award 2026 now open

Thu, 04 Sep 2025 08:30:00 PDT

The nomination period for the Broermann Medical Innovation Award 2026 has begun.

Grünenthal announces acquisition of the rights to Cialis® from Lilly in Mexico, Brazil & Colombia

Mon, 02 Jun 2025 01:00:00 PDT

Aachen, Germany, 2 June 2025 Grünenthal today announced the acquisition of the commercial rights to Cialis® (tadalafil) in Mexico, Brazil and Colombia from Eli Lilly and Company. Over the next few years, Grünenthal and Lilly will work together to transfer the manufacturing to Grünenthal's production site in Santiago, Chile, that will supply Cialis® for Mexico, Brazil and Colombia moving forward.

Biomay Launches FDA-Grade CRISPR/Cas9 Nuclease for Off-the-Shelf Purchase

Fri, 09 May 2025 03:00:00 PDT

Vienna, Austria May 9th 2025 Biomay, a leading manufacturer of recombinant proteins, today announced the commercial availability of its CRISPR/Cas9 nuclease, marking a significant addition to its off-the-shelf product portfolio for genome-editing applications.

Nomination period for the Broermann Medical Innovation Award started

Fri, 17 Jan 2025 02:30:00 PST

The nomination period for the Broermann Medical Innovation Award has started.

Grünenthal appoints Prof. Dr. Uli Brödl as Chief Scientific Officer

Thu, 09 Jan 2025 01:35:00 PST

Grünenthal announced today that Prof. Dr. Uli Brödl will assume the role of Chief Scientific Officer (CSO) and Member of the Corporate Executive Board, effective 01 February 2025.

Grünenthal and Averitas Pharma announce completion of recruitment for Phase III clinical trial with QUTENZA® in post-surgical neuropathic pain

Thu, 07 Nov 2024 01:45:00 PST

- The Phase III trial AV001 aims to evaluate QUTENZA® in post-surgical neuropathic pain (PSNP), a debilitating complication of surgery occurring after approximately 10 percent of all surgical procedures[1], thus affecting more than 3 million people with surgical procedures per year in the U.S.[2]

First participants enrolled in first-in-human Phase I clinical trial with nociceptin (NOP) receptor agonist

Tue, 22 Oct 2024 03:00:00 PDT

Aachen, Germany, 22 October 2024 Today, Grünenthal announced that the first participants have been enrolled in a first-in-human Phase I clinical trial for a nociceptin (NOP) receptor agonist. The trial will include 90 healthy volunteers and aims to demonstrate a favourable safety and tolerability profile and to confirm the pharmacokinetic characteristics of the compound after single and multiple ascending doses. The results of the trial are expected in Q3 2025.

Successful MDR Certification for AI Solution in Predicting Postoperative Complications New Product Generation for Optimized Patient Safety

Tue, 01 Oct 2024 21:00:00 PDT

x-cardiac, a leader in AI-based medical devices for the prediction of postoperative complications after cardiac surgery, is pleased to announce the successful MDR (Medical Device Regulation) certification of its new x-cardiac-platform.

Grünenthal appoints Dr. Jan Adams as Chief Commercial Officer

Mon, 30 Sep 2024 02:30:00 PDT

Aachen, Germany, 30 September 2024 Grünenthal announced today that Jan Adams, M.D., currently Chief Scientific Officer (CSO) and member of the Corporate Executive Board, will assume the role of Chief Commercial Officer (CCO) effective 1 October 2024. Prior to his role as CSO, he was Head of Strategy and Portfolio at Grünenthal.

RHEACELL announces FDA approval for Phase 3 study in refractory, non-curable CVU announced

Tue, 24 Sep 2024 03:45:00 PDT

- FDA approved blinded, multi-centric Phase-3 trial (NCT06489028) to investigate the safety and efficacy of allo-APZ2-CVU in patients with CVU

Acousia Therapeutics to present its clinical Phase 2 PROHEAR study on hearing loss treatment candidate ACOU085 at upcoming conferences

Mon, 12 Aug 2024 06:00:00 PDT

Acousia Therapeutics GmbH, a Tübingen-based clinical stage biotech company focused on the enhancement and preservation of natural hearing, will be presenting the ACOU085 Phase 2 PROHEAR clinical study at the HansonWade 4th Inner Ear Disorders Therapeutics Summit in Boston (MA) from August 2022, and at the 36th World Congress of Audiology from September 1922, 2024.

Grünenthal announces significant investments in its Latin America production sites, further securing reliable medicine supply for patients

Wed, 17 Jul 2024 00:15:00 PDT

Research Success in Rare Disease / RHEACELL receives positive signal for accelerated stem cell development program in rare Butterfly Disease'

Wed, 28 Feb 2024 06:00:00 PST

On February 29, 2024, Rare Disease Day will take place worldwide to raise awareness for rare diseases. Only 5% of the approximately 6,000 to 10,000 known rare diseases are currently treatable. The research and development of targeted therapeutic approaches is time-consuming, so that many companies shy away from the financial outlay in view of the low number of patients.

Hearing loss company Acousia announces first patient enrolled in its Phase 2 PROHEAR-Study

Thu, 15 Feb 2024 06:00:00 PST

Acousia Therapeutics GmbH, a Tübingen-based clinical stage biotech company focused on the enhancement and preservation of natural hearing, just announced the randomization of the first patient for the PROHEAR-Study. The PROHEAR-Study is a placebo-controlled, Phase 2a study with split-body design, which investigates the otoprotective efficacy of ACOU085 in patients with testicular cancer undergoing high-dose cisplatin-based chemotherapy regimens (cis-Pt ≥300 mg/m2).

RHEACELL announces "First Patient In": EB-Haus in Salzburg, Austria starts pivotal study for stem cell therapy

Tue, 27 Jun 2023 02:10:00 PDT

RHEACELL announces "First Patient In": EB-Haus in Salzburg, Austria starts pivotal study for stem cell therapy for severe forms of Epidermolysis bullosa that is longed for by those affected

Astrasana and Clever Leaves Partner to Establish International Supply Agreement For Medical Cannabis Extracts in Czech Republic and Switzerland

Wed, 31 May 2023 00:01:00 PDT

The Medias Hospital is Raising the Bar for Interventional Oncology as an IASIOS Enrolled Centre

Tue, 30 May 2023 07:30:00 PDT

The Medias Hospital has officially enrolled in the accreditation program of IASIOS to further ensure highest quality standards in Interventional Oncology as an important aspect of oncological patient care.

Grünenthal's resiniferatoxin receives Breakthrough Therapy Designation from U.S. FDA for pain associated with osteoarthritis of the knee

Mon, 22 May 2023 01:10:00 PDT

Aachen, Germany, 22 May 2023 Grünenthal today announced that its investigational non-opioid medicine resiniferatoxin (RTX), currently undergoing clinical Phase III development, received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for pain associated with osteoarthritis (OA) of the knee. The decision is based on clinical phase I and II data indicating significant pain relief and a favourable safety profile.

Artificial intelligence in intensive care units: University Hospital Freiburg relies on x-cardiac technology in clinical routine

Tue, 25 Apr 2023 23:00:00 PDT

Berlin-based x-cardiac GmbH is pleased to announce that Freiburg University Hospital has become the second pilot customer for its AI-based software "x-c-bleeding" for predicting severe bleeding complications after cardiac surgery. With the implementation of "x-c-bleeding", the University Hospital Freiburg takes another important step towards AI-based medicine.

Regulatory Trends in Medical Devices Report Ready for Download

Wed, 01 Mar 2023 00:00:00 PST

The report on regulatory trends in medical devices provides a comprehensive overview of the regulatory trends in medical devices and offers practical recommendations for companies looking to ensure compliance with these regulations

Breakthrough - EUR 50 million investment for start-up BrainRepair UG / Pivotal trial on stem cell treatment for brain damage in newborns fully funded

Wed, 08 Feb 2023 04:35:00 PST

Despite global economic and political crises, a London based group acquires 20% shares of BrainRepair UG, a spin-off of the Ruhr-University Bochum (RUB), Germany, that has developed a unique method based on own (autologous) cord blood stem cells to treat brain damage and cerebral palsy (CP) in newborns affecting 70,000 babies in the EU each year.